Recent Comments

Comment RSS

Adderall News and Research RSS Feed - Adderall News and Research

Adderall (dextroamphetamine-amphetamine) is a combination of two synthetic agents with central nervous system stimulant activity. Both agents are non-catecholamine, sympathomimetic agents that elevate blood pressure and cause bronchodilation. These agents are commonly abused psychostimulant drugs that induce psychologic dependence manifested by elevated mood, increased wakefulness, concentration, physical performance and a feeling of well-being. Tolerance to various effects develops unequally, so that tachycardia and enhanced alertness diminish while psychotoxic effects (hallucinations and delusions) may occur.

Teva Pharmaceutical Industries net sales up 25%

3. November 2009 03:19
Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2009. [More]

Posted in: Business / Finance

Tags: , , , , , , ,

Shire announces third quarter 2009 financial results

31. October 2009 02:51
Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009. [More]

KemPharm commences KP106 Phase 1 clinical trial for ADHD

22. October 2009 08:38
KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , ,

Shire settles pending ADDERALL XR litigation with Sandoz

14. October 2009 02:23
Shire plc, the global specialty biopharmaceutical company, announces that it has settled all pending litigation with Sandoz, Inc. ("Sandoz") in connection with Sandoz's Abbreviated New Drug Application ("ANDA") and its attempt to market generic versions of Shire's ADDERALL XR(R) (mixed amphetamine salts) for the treatment of Attention Deficit Hyperactivity Disorder. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: ,

KemPharm announces nomination of its second pipeline candidate

16. September 2009 08:53
KemPharm, Inc. today announced the nomination of its second pipeline candidate, KP201, based on its proprietary ligand activated therapy (LAT) platform. KP201 is a new chemical entity (NCE) for the treatment of pain with the possibility of reduced abuse potential. KP201 joins lead candidate KP106, which is a novel prodrug candidate in development for ADHD. [More]

Placebo effects in caregivers may change behavior of children with ADHD

29. June 2009 19:32
Stimulant medications, such as Ritalin and Adderall, are the accepted treatment to stem hyperactivity in children with attention deficit-hyperactive disorder (ADHD) and improve their behavior. [More]

Common ADHD drugs do not cause genetic damage in children

19. November 2008 18:14
In contrast to recent findings, two of the most common medications used to treat attention deficit hyperactivity disorder (ADHD) do not appear to cause genetic damage in children who take them as prescribed, according to a new study by researchers at the National Institutes of Health (NIH) and Duke University Medical Center. [More]

Genetic change in dopamine transporter supports a role for dopamine signaling in ADHD

9. July 2008 06:34
A genetic change in the dopamine transporter - one of the brain's dopamine-handling proteins - makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report this week in The Journal of Neuroscience. [More]

Study uncovers how Ritalin works in brain to boost cognition, focus attention

24. June 2008 21:31
Stimulant medications such as Ritalin have been prescribed for decades to treat attention deficit hyperactivity disorder (ADHD), and their popularity as "cognition enhancers" has recently surged among the healthy, as well. [More]

Preservatives and food colours may be the culprits in ADHD

25. May 2008 21:37
The suspicion that additives such as preservatives and artificial food colours can contribute to hyperactive behaviour in children has been around for years. [More]

Boffins admit to using drugs to enhance their thinking

9. April 2008 23:53
A survey of readers of a scientific journal has revealed that one in five use drugs to enhance their thinking. [More]

Top five prescribed drugs

21. September 2007 01:22
With a total nearly $5 billion, Lipitor, a cholesterol-reducing drug, ranked first in terms of total spending on prescription medicines by adults ages 18 to 64 in 2004, and another cholesterol-fighting drug, Zocor, ranked fourth at $2.3 billion, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. [More]

AHRQ and FDA to collaborate in ADHD study

21. September 2007 00:40
Two U.S. Department of Health and Human Services agencies will collaborate in the most comprehensive study to date of prescription medications used to treat attention deficit hyperactivity disorder (ADHD) and the potential for increased risk of heart attack, stroke or other cardiovascular problems. [More]

Largest study ever to look at possible heart risks with ADHD medications

18. September 2007 03:42
Two U.S. Department of Health and Human Services agencies will collaborate in the most comprehensive study to date of prescription medications used to treat attention deficit hyperactivity disorder (ADHD) and the potential for increased risk of heart attack, stroke or other cardiovascular problems. [More]

Ritalin abuse is on the rise among teens

11. May 2007 20:35
College is hard enough. But throw in end-of-semester exams, term papers and standardized tests, and there just aren't enough hours in the day. Enter Ritalin, the latest drug of choice among sleep-deprived students struggling to make the grade. [More]

Posted in: Drug Trial News

Tags: , , , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.